

1 **Dose-dependent response to infection with SARS-CoV-2 in the ferret**
2 **model: evidence of protection to re-challenge**

3

4 **Authors:**

5 Kathryn A. Ryan¹, Kevin R. Bewley¹, Susan A. Fotheringham¹, Phillip Brown¹, Yper
6 Hall¹, Anthony C. Marriott¹, Julia A. Tree¹, Lauren Allen¹, Marilyn J. Aram¹, Emily
7 Brunt¹, Karen R. Buttigieg¹, Breeze E. Cavell¹, Daniel P. Carter¹, Rebecca Cobb¹,
8 Naomi S. Coombes¹, Kerry J. Godwin¹, Karen E. Gooch¹, Jade Gouriet¹, Rachel
9 Halkerston¹, Debbie J. Harris¹, Holly E. Humphries¹, Laura Hunter¹, Catherine M. K.
10 Ho¹, Chelsea L. Kennard¹, Stephanie Leung¹, Didier Ngabo¹, Karen L. Osman¹,
11 Jemma Paterson¹, Elizabeth J. Penn¹, Steven T. Pullan¹, Emma Rayner¹, Gillian S.
12 Slack¹, Kimberley Steeds¹, Irene Taylor¹, Tom Tipton¹, Stephen Thomas¹, Nadina I.
13 Wand¹, Robert J. Watson¹, Nathan R. Wiblin¹, Sue Charlton¹, Bassam Hallis¹, Julian
14 A. Hiscox², Simon Funnell¹, Mike J. Dennis¹, Catherine J. Whittaker¹, Michael G.
15 Catton³, Julian Druce³, Francisco J. Salguero¹ & Miles W. Carroll^{1*}

16

17 **¹National Infection Service, Public Health England (PHE), Porton Down,**
18 **Salisbury, Wiltshire, United Kingdom SP4 0JG.**

19

20 **²Institute of Infection and Global Health, University of Liverpool, Liverpool,**
21 **United Kingdom, L69 2BE.**

22

23 **³Victorian Infectious Diseases Reference Laboratory, Royal Melbourne**
24 **Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria,**
25 **3000, Australia.**

26

27 ***Corresponding author**

28 Professor Miles Carroll

29 National Infection Service

30 Public Health England

31 Porton Down, Salisbury, Wiltshire, SP4 0JG

32 Email: miles.carroll@phe.gov.uk

33 Telephone: 01980 612100

34

35 **Running title: Ferret model of SARS-CoV-2**

36

37 **Keywords: Ferret, COVID, SARS-CoV-2, animal model, coronavirus**

38

39

40 **Abstract**

41

42 In December 2019 an outbreak of coronavirus disease (COVID-19) emerged in
43 Wuhan, China. The causative agent was subsequently identified and named severe
44 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which rapidly spread
45 worldwide causing a pandemic. Currently there are no licensed vaccines or
46 therapeutics available against SARS-CoV-2 but numerous candidate vaccines are in
47 development and repurposed drugs are being tested in the clinic. There is a vital need
48 for authentic COVID-19 animal models to further our understanding of pathogenesis
49 and viral spread in addition to pre-clinical evaluation of candidate interventions.

50

51 Here we report a dose titration study of SARS-CoV-2 to determine the most suitable
52 infectious dose to use in the ferret model. We show that a high (5×10^6 pfu) and medium
53 (5×10^4 pfu) dose of SARS-CoV-2 induces consistent upper respiratory tract (URT) viral
54 RNA shedding in both groups of six challenged animals, whilst a low dose (5×10^2 pfu)
55 resulted in only one of six displaying signs of URT viral RNA replication. The URT
56 shedding lasted up to 21 days in the high dose animals with intermittent positive signal
57 from day 14. Sequential culls revealed distinct pathological signs of mild multifocal
58 bronchopneumonia in approximately 5-15% of the lung, observed on day 3 in high and
59 medium dosed animals, with presence of mild broncho-interstitial pneumonia on day
60 7 onwards. No obvious elevated temperature or signs of coughing or dyspnoea were
61 observed although animals did present with a consistent post-viral fatigue lasting from
62 day 9-14 in the medium and high dose groups. After virus shedding ceased, re-
63 challenged ferrets were shown to be fully protected from acute lung pathology. The

64 endpoints of URT viral RNA replication in addition to distinct lung pathology and post
65 viral fatigue were observed most consistently in the high dose group. This ferret model
66 of SARS-CoV-2 infection presents a mild clinical disease (as displayed by 80% of
67 patients infected with SARS-CoV-2). In addition, intermittent viral shedding on days
68 14-21 parallel observations reported in a minority of clinical cases.

69

70

71

72 **Word count: 327**

73 Introduction

74

75 Coronaviruses are positive sense, single stranded RNA viruses belonging to the family
76 Coronaviridae¹. These viruses can infect a range of animals, including humans and
77 usually cause a mild respiratory infection, much like the common cold. Two highly
78 pathogenic coronaviruses have emerged in the human population in the last 20 years;
79 severe acute respiratory syndrome (SARS) CoV and middle eastern respiratory
80 syndrome (MERS) CoV. SARS-CoV infected approximately 8,000 people worldwide with
81 a case fatality rate (CFR) of 10%, while MERS-CoV has infected approximately 2,500
82 people with a CFR of 36%².

83

84 In December 2019 several pneumonia cases of unknown cause emerged in Wuhan,
85 Hubei, China. Deep sequencing analysis from lower respiratory tract samples from
86 patients indicated the cause to be a novel coronavirus³. The causative agent of this
87 novel coronavirus disease (COVID-19) was identified as SARS-CoV-2. As of May
88 22nd 2020, there have been over 4,893,000 confirmed cases reported worldwide,
89 including over 323,000 deaths, in over 180 countries⁴. The global mortality rate is yet
90 to be determined. Approximately 80% of patients display only mild symptoms, with
91 approximately 14% displaying severe symptoms such as dyspnoea and low blood
92 oxygen saturation. Around 6% of cases become critical, with respiratory failure, septic
93 shock and/or multiple organ failure⁵. There is an urgent need to develop suitable
94 animal models to evaluate antivirals or vaccine candidates against SARS-CoV-2.

95

96 Ferrets have been used extensively to model the disease caused by influenza virus⁶⁻
97 ¹² infection as well as human RSV^{13,14}, mumps virus¹⁵, Ebola virus^{16,17} and Nipah
98 virus^{18,19}. Due to the presence of ACE2, the virus receptor, on cells of the ferret
99 respiratory tract, these animals were developed as an effective model for SARS-
100 CoV²⁰⁻²³. The ferret has been shown to shed detectable virus from its URT as well as
101 exhibiting comparable clinical symptoms associated with milder cases of the
102 infection²¹ and shown similar pathology in the lung to that observed in humans²².
103 SARS-CoV-2 spike protein has been shown to exhibit many similarities in its amino
104 acid sequence and protein structure to the receptor binding domain of SARS-CoV²⁴
105 and also utilises ACE2 for cell entry²⁵, suggesting ferrets would be a potential model
106 for COVID-19.

107

108 To understand if ferrets are a suitable model for SARS-CoV-2 infection we challenged
109 animals intranasally with a range of titres of SARS-CoV-2 (5×10^2 , 5×10^4 and 5×10^6
110 pfu) in 1ml volume. The purpose was to characterise the most suitable challenge dose
111 for use in future studies, to aid understanding of the kinetics of viral pathogenesis and
112 the immune response following infection and to facilitate the evaluation of treatments
113 and vaccines against SARS-CoV-2.

114

115

116

117 **Results**

118

119 **Study Design.** Ferrets were challenged intranasally with 1ml of Victoria/1/2020²⁶
120 SARS-CoV-2 at three different titres representing a high, medium and low dose (**Table**
121 **1**). A high titre stock of challenge virus was prepared (passage 3), and quality control
122 sequencing showed it was identical to the original stock received from the Doherty
123 Institute and did not contain a commonly reported 8 amino acid deletion in the furin
124 cleavage site²⁷. Following the initial challenge, a re-challenge with the high dose
125 (5×10^6 PFU) took place at day 28 post challenge (pc). The four (two per group)
126 remaining ferrets in groups 2 and 3 were re-challenged via the same, intranasal, route
127 and 1ml volume alongside a control group of two naïve control ferrets (group 5).

128

129 **Viral Shedding following challenge.** Viral RNA was detected in the nasal wash of
130 6/6 ferrets in the high dose group from day 1 pc and continued to be detected at
131 varying levels until day 20 pc (**Fig. 1a**). The peak in viral RNA shedding was seen
132 between day 2 and 4 pc for all ferrets in the high dose group. Following a decline in
133 viral RNA (2/2 animals) to below the limit of quantification at day 13 pc, an increase
134 was seen at days 16 and 18, with a measurement in viral RNA for one ferret (4.75×10^4
135 copies/ml) just above the limit of quantification at day 16 pc and a viral load of 1.1×10^6
136 copies/ml in the other ferret at day 18 pc. Both Group 1 survivors were euthanised on
137 day 21 at which point no viral RNA was detected in their nasal washes.

138

139 In the medium dose group 6/6 ferrets also had detectable viral RNA in nasal washes
140 from day 1 pc. The peak of viral RNA shedding was more variable in the medium dose
141 group, with some ferrets peaking at days 2 to 3 pc (4/6) and others peaking at days 5
142 to 6 pc (2/6). A decline was then seen until day 11 pc where viral RNA levels fell below
143 the limit of quantification, but viral RNA was still detected. By day 16 no more viral
144 RNA was detected. Quantifiable viral RNA was only found in the nasal wash of 1/6
145 ferrets in the low challenge dose group. This ferret was euthanised on day 5 pc. No
146 other ferrets in the low dose group were found to shed quantifiable viral RNA in their
147 nasal wash.

148

149 A similar trend in the titre of viral RNA detected in nasal wash samples was observed
150 in the throat swabs samples during the first week after challenge (**Fig. 1b**). The
151 amount of viral RNA detected in the throat swab samples of ferrets in the high dose
152 group (6/6) peaked at day 3 pc. In contrast, however, detection of viral RNA in throat
153 swab samples was less prolonged than in the nasal passage, with no quantifiable viral
154 RNA detected past day 11 pc.

155

156 Detection of viral RNA in the rectal swabs was found to be variable across the different
157 dose groups (**Fig 1c.**). The highest viral RNA load was observed in a ferret in the high
158 dose group but there was a less consistent pattern of RNA detection which did not
159 continue past day 7 pc. In the medium dose group, 4/6 ferrets were found to have
160 detectable viral RNA in their rectal swabs between day 2 and 8 pc. No viral RNA was
161 detected in any of the rectal swabs collected from the low dose group following
162 challenge.

163

164 Viral RNA was detected at quantifiable levels in the bronchoalveolar lavage (BAL) of
165 each ferret euthanised (scheduled) on day 3 pc from the high dose (1/1) and medium
166 dose (1/1) groups (**Fig. 1d**). Viral RNA was detected but not quantified for ferrets
167 across all three challenge groups at day 5 and 7 pc. There was no viral RNA detected
168 in the BAL of any of the other ferrets after scheduled euthanasia. No viral RNA was
169 detected in the blood of ferrets from any group taken, as scheduled, on days 2, 5, 8,
170 11 and 14 pc (data not shown).

171

172 Illumina sequencing of nasal wash RNA extracts showed little variation between the
173 genome isolated at days 5 and 6 and the original sequence of the virus inoculated into
174 the ferrets. Only one non-synonymous SNP was identified, in the day five pc for a
175 ferret from the medium dose group; a T2152I mutation within the orf1ab polyprotein,
176 no further timepoints were collected for this animal as it was euthanised at day 5 pc.

177

178 **Clinical signs.** The normalised summed incidence of clinical scores for each group of
179 ferrets is shown in **Fig 2a** and total summed scores are shown in **Table 2**. At day 9 pc
180 all 3/3 ferrets in the high dose group showed reduced activity, a similar observation
181 was made in the medium dose group but later on day 10 pc. Reduced activity was
182 accompanied by ruffled fur, a sign that the ferrets were not grooming regularly. By
183 day 13 pc ferrets in the medium dose group stopped showing signs of reduced activity
184 and by day 15 pc the high dose groups stopped showing signs of reduced activity.
185 Ferrets in the high dose group had the highest normalised cumulative clinical score
186 (summed across all time points) (14.01), followed by the medium dose group (6.99)

187 with sporadic instances recorded in the low dose group. No fever ($> 39.9^{\circ}\text{C}$) was
188 detected in any ferret, in any group (**Fig. 2b**); instead body temperature remained
189 within the normal range. No weight loss was observed in any ferret in any group, below
190 baseline; however, the SARS-CoV-2 infected ferrets failed to gain as much weight as
191 the ferrets in the control (PBS) group, although this difference was not statistically
192 significant (**Fig. 2c**).

193

194 **Histopathology.** The nasal cavity from high dose ferrets showed a minimal to mild
195 necrosis of epithelial cells (**Fig. 3a**) from days 3 to 7 pc. However, abundant epithelial
196 cells from the nasal cavity were stained for viral RNA at day 3 pc (**Fig. 3b**). Occasional
197 scattered cells expressing viral RNA were observed in high dose animals at days 5
198 and 7 pc and medium dose animals at days 3, 5 and 7 pc. Similarly, very few scattered
199 epithelial cells were stained for viral RNA in the trachea and larynx from high and
200 medium dose animals at day 3, 5 and 7 pc.

201

202 No remarkable gross lesions were observed in the infected animals. Upon histological
203 examination of the lungs of ferrets from the high and medium dose groups, a mild
204 multifocal bronchopneumonia from day 3 to 14 pc was observed. Mild necrosis of the
205 bronchiolar epithelial cells was observed together with inflammatory cell infiltration of
206 neutrophils and mononuclear cells within the bronchiolar luminae, mostly affecting
207 animals from the high dose group at day 3, 5 and 7 pc (**Fig. 3c**). This
208 bronchopneumonia was characterised by the infiltration of inflammatory cells, mostly
209 neutrophils, but also macrophages and lymphocytes, in approximately 10-15% of the
210 lung section at day 3 pc decreasing to less than 5% at days 5 and 7 pc. The medium

211 dose group showed mild bronchopneumonia in less than 5% of the lung sections at
212 days 3 and 5 pc, while only occasional infiltration was observed in animals from the
213 low dose group. Few cells stained positive for viral RNA using *in situ* hybridisation
214 (RNAScope). Few type I and occasionally type II pneumocytes and alveolar
215 macrophages were positive for viral RNA at days 3, 5 and 7 pc (**Fig. 3d**) in high and
216 middle dose animals. Occasionally, mild proliferation of BALT was observed
217 surrounding damaged bronchi and bronchioles at the early stages of the disease, with
218 slightly more severity at day 14 and 21 pc (high dose) (**Fig. 3e**). Mild interstitial
219 pneumonia with an increase in the thickness of the interalveolar septa was observed
220 from day 3 pc towards the end of the experiment in high and medium dose groups
221 (**Fig. 3e**). Ferrets from the high dose group showed mild proliferation of type II
222 pneumocytes from day 7 pc onwards.

223

224 The liver showed multiple foci of inflammatory cell infiltration in the portal areas,
225 composed of mainly macrophages, lymphocytes and occasional plasma cells (**Fig. 3f**).
226 This multifocal infiltration was more severe in animals from the high and medium dose
227 groups from day 3 pc, compared to the low dose group or control (PBS) animals, which
228 only showed minimal presence of portal inflammation. No other remarkable changes
229 were observed in any other tissue. However, occasional positive cells (absorbing
230 epithelial enterocytes and goblet cells) were also observed in the small and large
231 intestine from high and medium dose at days 3, 5 and 7 pc.

232

233 **Antibody Response to SARS-CoV-2 Infection.** Neutralising antibody titres for
234 ferrets infected in the high dose and medium dose groups generally increased

235 longitudinally following challenge as illustrated in **Table 3**. The average fold increase
236 of neutralising antibodies from day 8 pc to day 14 pc was about the same for both the
237 high and medium dose groups. The low dose group had comparatively low
238 neutralising antibodies throughout the time course. One naïve sentinel group ferret
239 was shown to have strong neutralising antibodies to SARS-CoV-2 upon euthanasia at
240 day 20 pc. This ferret showed no clinical signs of SARS-CoV-2 infection and samples
241 taken at baseline, day 11 and day 20 post challenge were shown to be PCR negative
242 for SARS-CoV-2. Further there was no evidence for any pathology in any of the
243 tissues taken from both naïve sentinel ferrets euthanised on day 20 pc. Interestingly,
244 the cellular immune response seen in lung mononucleocytes (MNCs) (data not shown)
245 of the naïve sentinel ferret showed a high SARS-CoV-2 specific immune response to
246 whole live SARS-CoV-2, paralleling the high neutralising antibodies seen in the plaque
247 reduction neutralisation test for this ferret.

248

249

250 **Re-challenge of ferrets with high dose SARS-Cov-2 results in absence of lung**
251 **pathology.** Four previously infected ferrets, two from the medium and low dose
252 challenge groups, had neutralising titres of 1:274, 1:250, 1:82, and 1:55 at day 26 post
253 challenge respectively, see **Table 3**. At day 28 pc, these ferrets and two naïve control
254 animals were challenged intranasally with the high dose of SARS-Cov-2 (5×10^6 pfu).
255 Though URT infection was similar in all groups on day 2 post re-challenge (day 30 pc
256 for Groups 1-3), viral RNA levels subsequently decreased in the previously challenged
257 animals (n=4), with the medium dose group showing rapid decrease to below
258 quantifiable levels by day 5 post re-challenge (day 33 pc). Viral RNA levels continued

259 to stay above quantifiable levels in the naïve control group, although they began to fall
260 at day 8 post re-challenge (**Fig. 4a**). Similar results were seen in the throat swab and
261 rectal swabs (data not shown), with reduced viral shedding seen in the re-challenged
262 animals. Animals in the re-challenged medium and low dose groups exhibited weight
263 loss from baseline that was not seen at initial challenge for any of the animals in any
264 of the challenge groups (**Fig. 4b**). Re-challenged animals also experienced increased
265 clinical observations of lethargy and ruffled fur that was not observed at such an early
266 stage in the initial challenge (**Table 2**). In contrast, the two previously naïve control
267 animals did not experience weight loss below baseline after infection and they did not
268 suffer the same level of clinical observation as the re-challenged animals (**Fig 4b**).

269

270 The cellular immune response in the lungs of a low dose (Group 2) re-challenge ferret
271 and a naïve control (Group 5) ferret at day 36 (8 days post re-challenge respectively)
272 were compared. **Fig. 4c** shows SARS-CoV-2 specific cellular immune responses, as
273 determined by IFN- γ ELISpot. The number of secreting cells detected after re-
274 stimulation of lung MNCs with peptide pools spanning the spike protein varied between
275 ferrets from each group. The strongest response is detected in the re-challenge ferret
276 after ex-vivo re-stimulation with whole live virus. Upon histological examination the
277 upper and lower respiratory tracts from animals in both re-challenged groups showed
278 no remarkable lesions (**Fig. 4d and 4e**), and no presence of the significant
279 bronchopneumonia that was observed in ferrets challenged with 5×10^6 pfu for the first
280 time, i.e. the original high dose ferret or the naïve control infected group included for
281 the 're-challenge' (**Fig. 4f**). This parallels the absence of pathology observed in the
282 two naïve sentinel ferrets euthanised at day 20 pc.

283

284 Discussion

285

286 This study demonstrated that ferrets are susceptible to experimental intranasal
287 infection with a low passage isolate of SARS-CoV-2 strain Victoria 1. A high dose
288 (5×10^6 pfu/ml in a 1ml volume) intranasal challenge in ferrets produced mild clinical
289 signs, consistent lung pathology and a viral shedding pattern that aligns with the mild
290 to moderate disease seen in the human population.

291

292 Previously published SARS-CoV-1 challenge studies conducted in the ferret show that
293 a lower dose of that virus (10^3 TCID₅₀) is sufficient to cause a mild disease in the ferret
294 ^{20,21}. Here it was shown that a high (5×10^6 pfu) and medium (5×10^4 pfu) dose
295 intranasal challenge resulted in an infection characterised by prolonged viral RNA
296 shedding in all ferrets (days 1 -11 pc), accompanied by observable clinical signs from
297 day 8 post challenge for both high and medium dose groups. Onset of clinical
298 symptoms were delayed by approximately 24 hours in the medium dose animals. Both
299 doses also induced classical pathology of bronchial pneumonia involving 10% and 3%
300 of recipient lungs respectively. A low dose intranasal challenge of the same SARS-
301 CoV-2 virus (5×10^2 pfu) appeared to result in infection of only one ferret which shed
302 viral RNA in the upper respiratory tract and failed to show any remarkable lesions in
303 the respiratory tract.

304

305 In the high and medium dose groups, virus was readily detected using *in-situ*
306 hybridisation in the upper respiratory tract of ferrets, with a peak at 3 days post
307 challenge. These findings aligned with the detected shedding of viral RNA from nasal

308 washes which also peaked at day 3 to 4 post challenge. This upper respiratory
309 infection mirrors the clinical disease recently reported in mild cases of humans infected
310 with SARS-CoV-2 infection²⁸.

311

312 Recent reports indicate that COVID-19 patients appear to shed viral RNA intermittently
313 after recovery from disease with some individuals being tested and found to be positive
314 again after being released from isolation²⁹. This report is in alignment with the
315 observations in the two ferrets challenged with the high dose of SARS-CoV-2
316 (euthanised at day 21) which appeared to continue to shed detectable viral RNA from
317 the upper respiratory tract up to day 18 post challenge even though these animals had
318 developed neutralising antibodies.

319

320 The main histopathological finding in approximately 10% of the lung tissue sections in
321 the high dose group consisted mainly of a multifocal bronchiolitis, with inflammatory
322 infiltrates within the airways and some alveolar spaces. This finding is similar, but less
323 severe, to the findings in the published reports about SARS-CoV-1 ferret challenge
324 models^{22,30,31}. In this study, mild alveolar damage was observed in the acute phase.
325 At later time points, mild proliferation of type II pneumocytes, with interstitial infiltrates
326 and peribronchiolar cuffing, was recorded, consistent with evolution from the acute
327 phase.

328

329 Mild to moderate multifocal hepatic inflammatory cell infiltration has been widely
330 reported in viral infections in animals, and has been previously described in SARS-
331 CoV-1 infected ferrets³². However, the periportal infiltrates may not be associated with

332 injury to the surrounding tissue and they are reported as a common background finding
333 in laboratory ferret species. The presence of infected enterocytes has been reported
334 for SARS-CoV-1 and SARS-CoV-2 in humans³³ and different ferret models^{34,35} .

335

336 The upper respiratory virus replication, reported here, in the high and medium dose
337 groups of animals, support the observations of Shi *et al.*³⁴ who challenged ferrets with
338 10^5 pfu of SARS-CoV-2 and found peak levels of viral RNA (10^8 copies/ml) in nasal
339 washes on day 6. They also reported mild lung pathology associated with SARS-CoV-
340 2 infection similar to our medium dose animals, but this was not as extensive as that
341 seen in our high dose challenge group ferrets.

342

343 A ferret model of SARS-CoV-2 infection has also been developed by Kim *et al.*³⁵ who
344 used a challenge of 3×10^5 pfu which resulted in peak URT viral RNA shedding on day
345 4-6 which coincided with a significant temperature spike. In the present study, animals
346 challenged with either 5×10^4 or 5×10^6 pfu displayed a consistent fatigue after peak viral
347 shedding, however a significant increase in body temperature was not observed. This
348 fatigue after peak of viral shedding was not observed in the low dose group, ruling out
349 the possibility of it being induced by an aspect of ferret handling, such as sedation or
350 sampling.

351

352 Both Shi *et al.*³⁴ and Kim *et al.*³⁵ report live virus isolation from RNA positive nasal
353 wash samples. In this study, only low levels of live virus in some nasal washes and
354 throat swabs were detected even though high levels of viral RNA were detected. A
355 possible reason for this observation could be poor stability of this virus isolate, which

356 is currently untested, resulting in a knockdown of live virus between taking the samples
357 from a ferret and assaying the material. There may also have been an inhibitory effect
358 from the sample matrix in the cell cultures used for the live virus plaque assay.
359 Alternatively, this result may have accurately reflected low levels of viable virus
360 presence which others have reported even though viral RNA can be detected. For
361 human swabs and sputum samples, it has been noted that infectious virus was never
362 recovered from samples with a viral RNA load of less than 10^6 copies/ml²⁸.

363

364 Neutralising antibody levels developed in ferrets in all challenge groups within 14 days,
365 even though some animals in the low dose group were found to have no detectable
366 viral RNA shedding. The finding that low and medium dosed animals showed reduced
367 viral RNA shedding in the URT and an absence of lung pathology following re-
368 challenge is encouraging; it suggests that there may be potential benefits for the
369 healthy population as a result of naturally acquired immunity and is in line with the
370 observation reported by Bao *et al.*³⁶ in which previously infected rhesus macaques
371 were protected against re-challenge with SARS-CoV-2.

372

373 SARS-CoV-2 spike protein-specific immune responses seen in a low dose re-
374 challenged ferret were compared to that of a primary challenge ferret. This comparison
375 showed that the response to the virus appears to be higher on re-challenge.
376 However, ferrets challenged with our high dose of SARS-CoV-2 displayed increased
377 clinical observations and lost weight from baseline following re-challenge, hinting at
378 enhanced disease but a larger study would be required to effectively assess this
379 observation. Alternatively, these clinical signs may be perfectly normal host response

380 to infection in a pre-immune individual whilst the immune system is successfully
381 clearing a large challenge dose.

382

383 This study demonstrated that ferrets challenged with 5×10^6 pfu or 5×10^4 pfu displayed
384 only mild clinical signs of SARS-CoV-2 infection. These signs appeared to be less
385 severe than those reported after ferrets were infected with SARS-CoV-1^{21,30}.

386

387 This ferret model of intranasal SARS-CoV-2 infection presents three key measurable
388 endpoints: a) consistent URT viral RNA shedding; b) significant lung pathology; and
389 c) post viral fatigue. Reductions in URT RNA shedding during the first 14 days post
390 intranasal challenge could be an attractive indicator of the efficacy of candidate
391 therapeutics and vaccines. It may be wise, however, to euthanise prior to 14 days
392 post challenge to more accurately assess the impact on lung pathology especially
393 when looking for signs of vaccine-enhanced disease^{20,37,38}. Alternatively, if CT
394 scanning facilities were available, this may be achieved without the need to euthanise
395 a cohort if this technology was found suitable to also make this assessment. We
396 believe the high dose intranasal challenge will provide the most distinct disease
397 endpoints. However, with its reduced level of lung pathology, the medium dose
398 challenge may provide a higher level of sensitivity to some interventions, as was
399 observed when assessing therapeutics to influenza in the ferret model³⁹.

400

401 **Materials & Methods**

402

403 **Viruses and Cells.** SARS-CoV-2 Victoria/01/2020²⁶ was generously provided by The
404 Doherty Institute, Melbourne, Australia at P1 and passaged twice in Vero/hSLAM cells
405 [ECACC 04091501] Whole genome sequencing was performed, on the challenge
406 isolate, using both Nanopore and Illumina as described previously⁴⁰. Virus titre was
407 determined by plaque assay on Vero/E6 cells [ECACC 85020206]. Cell lines were
408 obtained from the European Collection of Authenticated Cell Cultures (ECACC) PHE,
409 Porton Down, UK. Cell cultures were maintained at 37°C in MEM (Life Technologies,
410 California, USA) supplemented with 10% foetal bovine serum (Sigma, Dorset, UK) and
411 25 mM HEPES (Life Technologies).

412

413 **Animals.** Twenty-two healthy, female ferrets (*Mustela putorius furo*) ages 7 months
414 were obtained from a UK Home Office accredited supplier (Highgate Farm, UK). The
415 mean weight at the time of challenge was 1032g/ferret (range 870-1239g). Animals
416 were housed in pairs at Advisory Committee on Dangerous Pathogens (ACDP)
417 containment level 3. Cages met with the UK Home Office *Code of Practice for the*
418 *Housing and Care of Animals Bred, Supplied or Used for Scientific Procedures*
419 (December 2014). Access to food and water was *ad libitum* and environmental
420 enrichment was provided. All experimental work was conducted under the authority of
421 a UK Home Office approved project licence that had been subject to local ethical
422 review at PHE Porton Down by the Animal Welfare and Ethical Review Body (AWERB)
423 as required by the *Home Office Animals (Scientific Procedures) Act 1986*.

424

425 **Experimental Design.** Before the start of the experiment animals were randomly
426 assigned to challenge groups, to minimise bias. The weight distribution of the animals
427 was tested to ensure there was no statistically significant difference between groups
428 (one-way ANOVA, $p > 0.05$). An identifier chip (Bio-Thermo Identichip, Animalcare Ltd,
429 UK) was inserted subcutaneously into the dorsal cervical region of each animal. Prior
430 to challenge animals were sedated by intramuscular injection of ketamine/xylazine
431 (17.9 mg/kg and 3.6 mg/kg bodyweight). Challenge virus was delivered by intranasal
432 instillation (1.0 ml total, 0.5 ml per nostril) diluted in phosphate buffered saline (PBS).

433

434 Three different doses of virus were delivered to three groups (n=6) of ferrets: high
435 [5×10^6 pfu/ml], medium [5×10^4 pfu/ml] and a low [5×10^2 pfu/ml] dose. For the high,
436 medium and low dose groups, individual ferrets were scheduled for euthanasia on day
437 3 (n=1), day 5 (n=1), day 7 (n=1) and day 14 (n=1). For the high dose group, the
438 remaining 2 ferrets were euthanised on day 21 (n=2). The mock-infected animals (n=2)
439 received an intranasal instillation of sterile PBS and were euthanised on day 20.

440

441 On day 28 pc the remaining ferrets in the low (n=2) and medium (n=2) groups were
442 re-challenged with 5×10^6 pfu by the intranasal route. Additional naïve control ferrets
443 (n=2) were also challenged on day 28, to provide a re-challenge control. All 6 animals
444 were monitored for clinical signs and one ferret from each group was euthanised on
445 day 33 and the remaining animals were euthanised on day 36.

446

447 Nasal washes, throat and rectal swabs were taken at days -1, 1-8, 10, 11, 13, 14, 16,
448 18 and 20 pc. They were also taken at days 1-5 and 8 post re challenge (days 29-33
449 and 36 pc). Whole blood and serum were collected at 2, 5, 8, 11, 14 days pc for all

450 ferrets. Whole blood and serum were collected at days 2, 5 and 8 (days 30, 33 and 36
451 pc) post re-challenge for all remaining ferrets. The negative control ferrets (n=2) had
452 nasal washes, throat swabs, whole blood and serum taken at -1 and 11 days pc. At
453 necropsy nasal washes, throat and rectal swabs, whole blood and serum were taken
454 alongside tissue samples for histopathology. Nasal washes were obtained by flushing
455 the nasal cavity with 2 ml PBS. For throat swabs, a flocked swab (MWE Medical Wire,
456 Corsham, UK) was gently stroked across the back of the pharynx in the tonsillar area.
457 Throat and rectal swabs were processed, and aliquots stored in viral transport media
458 (VTM) and AVL at -80C until assay.

459

460 **Clinical and euthanasia observations.** Animals were monitored for clinical signs of
461 disease four times daily (approximately 6 hours apart) for the first 5 days pc and then
462 twice daily (approximately 8 hours apart) for the remaining time. Clinical signs of
463 disease were assigned a score based upon the following criteria. Activity was scored
464 as follows; 0 = alert and playful, 1 = alert, playful when stimulated, 2 = alert, not playful
465 when stimulated, 3 = not alert or playful. Ruffled fur was given a score of 1. No other
466 clinical signs were noted. In order to meet the requirement of the project license,
467 immobility, neurological signs or a sudden drop in temperature were automatic
468 euthanasia criteria. Animals were also deemed to have reached a humane endpoint
469 if their body weight was at or below 30% baseline. If any ferret reached any of these
470 three euthanasia criteria, they were to be immediately euthanised using a UK Home
471 Office approved Schedule 1 procedure. However, no animals reached these end-
472 points during this study.

473

474 Temperature was taken using a microchip reader and implanted temperature/ID chip.
475 Temperature was recorded at each clinical scoring point using the chip to ensure any
476 peak of fever was recorded. Animals were weighed at the same time of each day from
477 the day before infection until euthanasia.

478

479 **Necropsy Procedures.** Ferrets were anaesthetised with ketamine/xylazine (17.9
480 mg/kg and 3.6 mg/kg bodyweight) and exsanguination was effected via cardiac
481 puncture, followed by injection of an anaesthetic overdose (sodium pentobarbitone
482 Dolelethal, Vetquinol UK Ltd, 140 mg/kg). A necropsy was performed immediately
483 after confirmation of death. The bronchoalveolar lavage (BAL) was collected at
484 necropsy from the right lung. The left lung was dissected prior to BAL collection and
485 used for subsequent histopathology and virology procedures.

486

487 **RNA Extraction.** RNA was extracted using a Viral RNA QIAamp kit (Qiagen) following
488 manufacturer's instruction. RNA was isolated from nasal wash, throat and rectal
489 swabs, EDTA treated whole blood and BAL.

490

491

492 **Quantification of Viral Loads by RT-qPCR.** Reverse transcription-quantitative
493 polymerase chain reaction (RT-qPCR) targeting a region of the SARS-CoV-2
494 nucleocapsid (N) gene was used to determine viral loads and was performed using
495 TaqPath™ 1-Step RT-qPCR Master Mix, CG (Applied Biosystems™), 2019-nCoV
496 CDC RUO Kit (Integrated DNA Technologies) and 7500 Fast Real-Time PCR System
497 (Applied Biosystems™) was used. Sequences of the N1 primers and probe were:
498 2019-nCoV_N1-forward, 5' GACCCCAAATCAGCGAAAT 3'; 2019-nCoV_N1-

499 reverse, 5' TCTGGTTACTGCCAGTTGAATCTG 3'; 2019-nCoV_N1-probe, 5' FAM-
500 ACCCCGCATTACGTTTGGTGGACC-BHQ1 3'. The cycling conditions were: 25°C
501 for 2 minutes, 50°C for 15 minutes, 95°C for 2 minutes, followed by 45 cycles of 95°C
502 for 3 seconds, 55°C for 30 seconds. The quantification standard was a 100bp Ultramer
503 RNA oligo (Integrated DNA Technologies) equivalent to 28274-28373bp of SARS-
504 CoV-2 NC_045512.2, with quantification between 1×10^1 and 1×10^7 copies/ μ l.
505 Positive samples detected below the limit of quantification were assigned the value of
506 6 copies/ μ l, whilst undetected samples were assigned the value of ≤ 2 copies/ μ l,
507 equivalent to the assays limit of detection.

508

509 **SARS-CoV-2 virus plaque assay.** Samples were diluted in serum-free MEM
510 containing antibiotic/antimycotic (Life Technologies) and incubated in 24-well plates
511 (Nunc, ThermoFisher Scientific, Loughborough, UK) with Vero E6 cell monolayers.
512 Virus was allowed to adsorb at 37 °C for 1 hour, then overlaid with MEM containing
513 1.5% carboxymethylcellulose (Sigma), 4% (v/v) foetal bovine serum (Sigma) and 25
514 mM HEPES buffer (Life Technologies). After incubation at 37 °C for 5 days, they were
515 fixed overnight with 20% (w/v) formalin/PBS, washed with tap water and stained with
516 methyl crystal violet solution (0.2% v/v) (Sigma).

517

518

519 **Plaque Reduction Neutralisation Test.** Neutralising virus titres were measured in
520 heat-inactivated (56°C for 30 min) serum samples. SARS-CoV-2 was diluted to a
521 concentration of 933 pfu/ml (70 pfu/75 μ l) and mixed 50:50 in 1% FCS/MEM with
522 doubling serum dilutions from 1:10 to 1:320 in a 96-well V-bottomed plate. The plate

523 was incubated at 37°C in a humidified box for 1 hour to allow the antibody in the serum
524 samples to neutralise the virus. The neutralised virus was transferred into the wells of
525 a washed plaque assay 24-well plate (see plaque assay method), allowed to adsorb
526 at 37°C for a further hour, and overlaid with plaque assay overlay media. After 5 days
527 incubation at 37°C in a humified box, the plates were fixed, stained and plaques
528 counted. Median neutralising titres (ND₅₀) were determined using the Spearman-
529 Karber ⁴¹ formula relative to virus only control wells.

530

531 **Histopathological Analysis.** Samples from the left cranial and left caudal lung lobe
532 together with spleen, kidney, liver, tracheobronchial and axillary lymph nodes,
533 jejunum, colon, trachea, larynx and nasal cavity, were fixed by immersion in 10%
534 neutral-buffered formalin and processed routinely into paraffin wax. Nasal cavity
535 samples were decalcified using an EDTA-based solution prior to embedding. 4 µm
536 sections were cut and stained with haematoxylin and eosin (H&E) and examined
537 microscopically. In addition, samples were stained using the RNAscope technique to
538 identify the SARS-CoV-2 virus RNA. Briefly, tissues were pre-treated with hydrogen
539 peroxide for 10 minutes (room temperature), target retrieval for 15 mins (98-101°C)
540 and protease plus for 30 mins (40°C) (Advanced Cell Diagnostics). A V-nCoV2019-S
541 probe (Cat No. 848561, Advanced Cell Diagnostics) was incubated on the tissues for
542 2 hours at 40°C. Amplification of the signal was carried out following the RNAscope
543 protocol using the RNAscope 2.5 HD Detection kit – Red (Advanced Cell Diagnostics).

544

545

546 **Isolation of Lung Mononuclear Cells.** Whole lungs were removed from each
547 ferret. The lungs were dissected into small pieces and placed into a 12.5ml solution
548 of collagenase (715 collagenase units/ml) (Sigma-Aldrich) and DNase (350 DNase
549 units/ml) (Sigma-Aldrich). Lungs were placed into gentleMACS C-tubes and agitated
550 whilst incubating at 100rpm, 37°C for 1 hour on an OctoMACS (Miltenyi Biotec, Surrey,
551 UK). Partially digested lung tissue was then dissociated using an OctoMACS. The
552 tissue solution was passed through two cell sieves (100µm then 70µm) and then
553 layered with Ficoll®- Paque Premium (GE Healthcare, Hatfield, United Kingdom).
554 Density gradient centrifugation was carried out at 400g for 30 minutes. Buffy coats
555 containing lymphocytes were collected and washed with medium by pelleting cells via
556 centrifugation at 400 g for 10 minutes. The cells were counted using a vial-1 cassette
557 and a Nucleocounter-200 before cryopreservation in 95% FCS/ 5% v/v DMSO.
558 Cryopreserved cells were then frozen at -80°C in controlled rate freezer containers
559 overnight, before transfer to liquid nitrogen (vapour phase).

560

561 **Interferon-gamma (IFN-γ) ELISpot Assay.** An IFN-γ ELISpot assay was performed
562 to determine the production capacity of SARS-CoV-2-specific T cells in the lung using
563 a ferret IFN-γ kit (Mab-tech, Nacka, Sweden). Lung MNCs were defrosted into pre-
564 warmed medium (R10) consisting of RPMI 1640 medium (Sigma-Aldrich)
565 supplemented with 2mM L-glutamine (Sigma-Aldrich), 0.05mM 2-mercaptoethanol
566 (Invitrogen, Paisley, United Kingdom), 25mM HEPES buffer (Sigma-Aldrich, Dorset,
567 United Kingdom), 100 U/ml Penicillin/100 µg/ml Streptomycin solution (Sigma-
568 Aldrich), 10% heat inactivated foetal bovine serum (Sigma-Aldrich), and benzonase
569 (Novogen, Merck, Darmstadt, Germany). Cells were rested for 2 hours prior to
570 use. Lung MNCs were assessed for responses to whole SARS-CoV-2 virus and a

571 COVID-19 Spike Protein (GenBank: QHQ82464.1) peptide panel. The peptide panel
572 consisted of 15mer peptides overlapping by 11mers. Individual peptides were
573 reconstituted in 10% v/v DMSO. The 10 peptide pools, each containing 32 peptides,
574 were created by combining equimolar amounts of each peptide. Three mega pools
575 spanning the whole spike protein (approx. 100 peptides in each mega pool) were also
576 created. Each peptide pool and mega pool was diluted for use in the ELISpot assay in
577 supplemented RPMI to achieve a final concentration of at 2.5µg per peptide. SARS-
578 CoV-2 whole virus was also used at an MOI of 0.09 to re-stimulate the lung
579 MNCs. The virus was cell culture grown and was a direct match to the isolate used
580 for ferret challenge. R10 media was used as a negative control and for preparation
581 and dilution of cells, peptide, virus and stimulants. Cell stimulation cocktail
582 (PMA/Ionomycin 500x concentrate, Sigma-Aldrich, Dorset, United Kingdom), was
583 used as a positive control to prove cells were capable of a stimulation response. Pre-
584 coated ferret anti- IFN-γ ELISpot plates (mAb MTF14, Mab-tech, Nacka, Sweden)
585 were used and 500,000 lung MNCs were plated per well in 50µl of R10, with or without
586 antigen, in duplicate and incubated overnight (37°C, 5% CO₂). Following cell
587 stimulation, plates were washed 5x with 1x PBS (Gibco) and incubated at RT for 2
588 hours with biotinylated anti IFN-γ IgG. The plates were then washed 5x with 1x PBS
589 and incubated with streptavidin-ALP for 1 hour, RT. The plates were washed again
590 5x with 1x PBS and spots were developed with 5-bromo-4-chloro-3-indoly phosphate
591 (BCIP)-Nitro Blue tetrazolium (NBT) substrate. Plates were allowed to dry overnight
592 and decontaminated by formaldehyde fumigation before removal from the CL3 facility.
593 Plates were read, counted and quality control checked using the CTL ELISpot plate
594 reader and ImmunoSpot 5.0 analyser software. Results from duplicate test wells were

595 averaged. Data were corrected for background by subtracting the mean number of
596 spots from the R10 media control wells from the mean counts of spots in the test wells.

597

598 **Acknowledgements**

599 The authors gratefully acknowledge the support from the Biological Investigations
600 Group at the National Infection Service, PHE, Porton Down, United Kingdom. The
601 views expressed in this paper are those of the authors and not necessarily those of
602 the funding body. This work was funded by the US Food and Drug Administration
603 [Contract number: HHSF223201710194C].

604

605 **Conflicts of Interest**

606 No conflicts of interest declared.

607

608 **Contributions**

609

610 K.A.R, Y.H, S.G.F, C.J.W, J.A.H and M.W.C. conceived the study.

611 J.D. and M.C. provided virus strain.

612 K.R.B. grew viral stock, optimised virology techniques and supervised virology
613 experiments.

614 S.A.F, D.J.H, I.T. and N.R.W performed all animal procedures at containment level 3.

615 K.A.R, P.B, B.E.C, K.G, C.M.K.H, D.N, K.S and S.T processed all animal samples at
616 containment level 3.

617 L.H, C.L.K, E.R and F.J.S contributed to histology experiments and performed critical
618 assessment of pathology.

619 L.A, E.B, K.R.B, N.S.C, K.J.G, H.E.H, S.L and E.J.P contributed wet virology
620 experiments and analysis of data.

621 K.A.R, L.A, E.B, J.G. R.H, S.L J.P, K.S and N.I.W contributed to inactivation, extraction
622 and PCR of samples

623 G.S performed quality control and analytical assistance on PCR data

624 D.P.C, S.T.P and K.L.O performed NGS and analysis data.

625 K.A.R performed analysis on data generated

626 T.T, R.W and M.J.D provided technical assistance

627 K.A.R, J.A.T, F.J.S and M.W.C wrote the manuscript

628 A.C.M, C.J.W, K.S, B.E.C and S.G.F. provided critical review

629

630 **References**

631 1 Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses.
632 *Nature Reviews Microbiology* **17**, 181-192, doi:10.1038/s41579-018-0118-9
633 (2019).

634 2 Sutton, T. C. & Subbarao, K. Development of animal models against emerging
635 coronaviruses: From SARS to MERS coronavirus. *Virology* **479-480**, 247-258,
636 doi:10.1016/j.virol.2015.02.030 (2015).

637 3 Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel
638 coronavirus: implications for virus origins and receptor binding. *The Lancet* **395**,
639 565-574, doi:10.1016/S0140-6736(20)30251-8 (2020).

640 4 WHO. *WHO Coronavirus Disease (COVID-19) Dashboard*,
641 <<https://covid19.who.int/>> (2020).

642 5 WHO. *Report of the WHO-China Joint Mission on Coronavirus Disease 2019*
643 *(COVID-19)*, <[https://www.who.int/docs/default-source/coronaviruse/who-](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf)
644 [china-joint-mission-on-covid-19-final-report.pdf](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf)> (2020).

645 6 Maines, T. R. *et al.* Transmission and Pathogenesis of Swine-Origin 2009
646 A(H1N1) Influenza Viruses in Ferrets and Mice. *Science* **325**, 484-487,
647 doi:10.1126/science.1177238 (2009).

648 7 Gustin, K. M. *et al.* Influenza virus aerosol exposure and analytical system for
649 ferrets. *Proceedings of the National Academy of Sciences* **108**, 8432-8437,
650 doi:10.1073/pnas.1100768108 (2011).

- 651 8 Chen, K. S., Bharaj, S. S. & King, E. C. Induction and relief of nasal congestion
652 in ferrets infected with influenza virus. *International Journal of Experimental*
653 *Pathology* **76**, 55-64 (1995).
- 654 9 Belser, J. A., Eckert, A. M., Tumpey, T. M. & Maines, T. R. Complexities in
655 Ferret Influenza Virus Pathogenesis and Transmission Models. *Microbiol Mol*
656 *Biol Rev* **80**, 733-744, doi:10.1128/MMBR.00022-16 (2016).
- 657 10 Ryan, K. A. *et al.* Cellular immune response to human influenza viruses differs
658 between H1N1 and H3N2 subtypes in the ferret lung. *PLoS one* **13**, e0202675-
659 e0202675, doi:10.1371/journal.pone.0202675 (2018).
- 660 11 Gooch, K. E. *et al.* Heterosubtypic cross-protection correlates with cross-
661 reactive interferon-gamma-secreting lymphocytes in the ferret model of
662 influenza. *Scientific reports* **9**, 2617-2617, doi:10.1038/s41598-019-38885-0
663 (2019).
- 664 12 Thangavel, R. R. & Bouvier, N. M. Animal models for influenza virus
665 pathogenesis, transmission, and immunology. *Journal of Immunological*
666 *Methods* **410**, 60-79, doi:<http://dx.doi.org/10.1016/j.jim.2014.03.023> (2014).
- 667 13 Stittelaar, K. J. *et al.* Ferrets as a Novel Animal Model for Studying Human
668 Respiratory Syncytial Virus Infections in Immunocompetent and
669 Immunocompromised Hosts. *Viruses* **8**, 168, doi:10.3390/v8060168 (2016).
- 670 14 Taylor, G. Animal models of respiratory syncytial virus infection. *Vaccine* **35**,
671 469-480, doi:10.1016/j.vaccine.2016.11.054 (2017).
- 672 15 Xu, P. *et al.* Infection of mice, ferrets, and rhesus macaques with a clinical
673 mumps virus isolate. *Journal of virology* **87**, 8158-8168, doi:10.1128/JVI.01028-
674 13 (2013).
- 675 16 Kozak, R. *et al.* Ferrets Infected with Bundibugyo Virus or Ebola Virus
676 Recapitulate Important Aspects of Human Filovirus Disease. *Journal of*
677 *Virology* **90**, 9209, doi:10.1128/JVI.01033-16 (2016).
- 678 17 de La Vega, M.-A. *et al.* Modeling Ebola Virus Transmission Using Ferrets.
679 *mSphere* **3**, e00309-00318, doi:10.1128/mSphere.00309-18 (2018).
- 680 18 Albrecht, R. A. *et al.* Moving Forward: Recent Developments for the Ferret
681 Biomedical Research Model. *mBio* **9**, e01113-01118, doi:10.1128/mBio.01113-
682 18 (2018).

- 683 19 Clayton, B. A. *et al.* The Nature of Exposure Drives Transmission of Nipah
684 Viruses from Malaysia and Bangladesh in Ferrets. *PLOS Neglected Tropical*
685 *Diseases* **10**, e0004775, doi:10.1371/journal.pntd.0004775 (2016).
- 686 20 Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified
687 vaccinia virus Ankara based recombinant SARS vaccine in ferrets. *Vaccine* **23**,
688 2273-2279, doi:<https://doi.org/10.1016/j.vaccine.2005.01.033> (2005).
- 689 21 Chu, Y.-K. *et al.* The SARS-CoV ferret model in an infection-challenge study.
690 *Virology* **374**, 151-163, doi:10.1016/j.virol.2007.12.032 (2008).
- 691 22 van den Brand, J. M. A. *et al.* Pathology of Experimental SARS Coronavirus
692 Infection in Cats and Ferrets. *Veterinary Pathology* **45**, 551-562,
693 doi:10.1354/vp.45-4-551 (2008).
- 694 23 Darnell, M. E. R. *et al.* Severe acute respiratory syndrome coronavirus infection
695 in vaccinated ferrets. *The Journal of infectious diseases* **196**, 1329-1338,
696 doi:10.1086/522431 (2007).
- 697 24 Wu, F. *et al.* A new coronavirus associated with human respiratory disease in
698 China. *Nature* **579**, 265-269, doi:10.1038/s41586-020-2008-3 (2020).
- 699 25 Gralinski, L. E. & Menachery, V. D. J. V. Return of the Coronavirus: 2019-nCoV.
700 **12**, 135 (2020).
- 701 26 Caly, L. *et al.* Isolation and rapid sharing of the 2019 novel coronavirus (SARS-
702 CoV-2) from the first patient diagnosed with COVID-19 in Australia. **n/a**,
703 doi:10.5694/mja2.50569.
- 704 27 Davidson, A. D. *et al.* Characterisation of the transcriptome and proteome of
705 SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry
706 reveals evidence for a cell passage induced in-frame deletion in the spike
707 glycoprotein that removes the furin-like cleavage site. *bioRxiv*,
708 2020.2003.2022.002204, doi:10.1101/2020.03.22.002204 (2020).
- 709 28 Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-
710 2019. *Nature*, doi:10.1038/s41586-020-2196-x (2020).
- 711 29 Mahase, E. Covid-19: WHO and South Korea investigate reconfirmed cases.
712 *BMJ* **369**, m1498, doi:10.1136/bmj.m1498 (2020).
- 713 30 Martina, B. E. E. *et al.* SARS virus infection of cats and ferrets. *Nature* **425**,
714 915-915, doi:10.1038/425915a (2003).

- 715 31 ter Meulen, J. *et al.* Human monoclonal antibody as prophylaxis for SARS
716 coronavirus infection in ferrets. *The Lancet* **363**, 2139-2141,
717 doi:[https://doi.org/10.1016/S0140-6736\(04\)16506-9](https://doi.org/10.1016/S0140-6736(04)16506-9) (2004).
- 718 32 Weingartl, H. *et al.* Immunization with Modified Vaccinia Virus Ankara-Based
719 Recombinant Vaccine against Severe Acute Respiratory Syndrome Is
720 Associated with Enhanced Hepatitis in Ferrets. **78**, 12672-12676,
721 doi:10.1128/JVI.78.22.12672-12676.2004 %J Journal of Virology (2004).
- 722 33 Lamers, M. M. *et al.* SARS-CoV-2 productively infects human gut enterocytes.
723 eabc1669, doi:10.1126/science.abc1669 %J Science (2020).
- 724 34 Shi, J. *et al.* Susceptibility of ferrets, cats, dogs, and other domesticated animals
725 to SARS–coronavirus 2. *Science*, eabb7015, doi:10.1126/science.abb7015
726 (2020).
- 727 35 Kim, Y.-I. *et al.* Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.
728 *Cell Host & Microbe*, doi:<https://doi.org/10.1016/j.chom.2020.03.023> (2020).
- 729 36 Bao, L. *et al.* Reinfection could not occur in SARS-CoV-2 infected rhesus
730 macaques. *bioRxiv*, 2020.2003.2013.990226, doi:10.1101/2020.03.13.990226
731 (2020).
- 732 37 Tseng, C.-T. *et al.* Immunization with SARS Coronavirus Vaccines Leads to
733 Pulmonary Immunopathology on Challenge with the SARS Virus. *PLOS ONE*
734 **7**, e35421, doi:10.1371/journal.pone.0035421 (2012).
- 735 38 Bolles, M. *et al.* A double-inactivated severe acute respiratory syndrome
736 coronavirus vaccine provides incomplete protection in mice and induces
737 increased eosinophilic proinflammatory pulmonary response upon challenge.
738 *Journal of virology* **85**, 12201-12215, doi:10.1128/JVI.06048-11 (2011).
- 739 39 Marriott, A. C. *et al.* Low Dose Influenza Virus Challenge in the Ferret Leads to
740 Increased Virus Shedding and Greater Sensitivity to Oseltamivir. *PLoS ONE* **9**,
741 e94090, doi:10.1371/journal.pone.0094090 (2014).
- 742 40 Lewandowski, K. *et al.* Metagenomic Nanopore Sequencing of Influenza Virus
743 Direct from Clinical Respiratory Samples. *Journal of Clinical Microbiology* **58**,
744 e00963-00919, doi:10.1128/JCM.00963-19 (2019).
- 745 41 Grist, N. R. Diagnostic methods in clinical virology. (1966).

746

747


748 **Figures & Tables**

749

750 **Table 1 Experimental Animal Groups.**

Group		Number of Animals	Initial Challenge Virus Titre (pfu/ml)	Re-challenge Virus Titre (pfu/ml)	Euthanasia/ challenge days
1	High	6	5×10^6		1 ferret euthanised at day 3, 5, 7, 14 pc 2 ferrets euthanised day at 21 pc
2	Medium	6	5×10^4	5×10^6	1 ferret euthanised at days 3, 5, 7, 14 pc 2 ferrets re-challenged at day 28 pc 1 ferret euthanised at days 33 & 36 pc
3	Low	6	5×10^2	5×10^6	1 ferret euthanised at days 3, 5, 7, 14 pc 2 ferrets re-challenged at day 28 pc 1 ferret euthanised at days 33 & 36 pc
4	Naïve Sentinel	2	PBS		2 ferrets euthanised at day 20 pc
5	Naïve Control	2		5×10^6	1 ferret euthanised at days 33 & 36 pc


751 A total of 22 ferrets were distributed across 5 groups. All inoculations were performed
752 intranasally with 1ml of fluid. N/A, not applicable, pc, post-challenge.



753

754 **Figure 1. Viral RNA Shedding** Nasal washes and swabs were collected at days 1 to
755 8, 10, 11, 13, 14, 16, 18 & 20 pc for all virus challenged groups. Viral RNA was
756 quantified by RT-qPCR. No viral RNA was detected in any samples taken from the
757 naïve sentinel ferrets (data not shown). (a) Nasal washes (b) Throat swabs (c) Rectal
758 swabs (d) Bronchoalveolar lavage collected at necropsy (numbers indicate day post
759 challenge the ferret was euthanised). Points show values for individual animals, lines
760 show group geometric means. The dashed horizontal lines show the lower limit of
761 quantification (LoQ) and the lower limit of detection (LoD).

762



763

764 **Figure 2. Clinical Observations.** (a) Clinical observations were carried out four times
765 daily (approximately 6 hours apart) for the first 5 days and then twice daily


766 (approximately 8 hours apart) for the remaining time. Observations were summed for
 767 each group and normalised for the number of ferrets. (b) Temperatures were taken at
 768 the same time as clinical observations, using the identifier chip, to ensure any peak of
 769 fever was recorded. Mean temperatures are displayed on the graph. (c) Weight was
 770 recorded daily and percentage weight change from baseline was plotted. Points show
 771 values for individual animals, lines show group means.

772 **Table 2 Clinical Scores**

Group		Clinical Scores (individual instances summed)					
		Initial Challenge	Day 0 to 7 post challenge	Day 8 to 14 post challenge	Day 15 to 21 post challenge	Re-challenge	Day 0 to 8 post re-challenge
1	High	1 ferret euthanised at day 3, 5, 7, 14 pc 2 ferrets euthanised at day 21 pc	Activity =1; 2	Activity =1; 19 Ruffled fur; 12	Activity =1; 2		
2	Medium	1 ferret euthanised at day 3, 5, 7, 14 pc	Activity =1; 2	Activity =1; 12 Ruffled fur; 8	0	1 ferret euthanised at day 5 & 8 post re-challenge	Activity =1; 4 Activity =2; 2 Ruffled fur; 1
3	Low	1 ferret euthanised at day 3, 5, 7, 14 pc	Activity =1; 1 Sneeze; 1	Activity =1; 1	0	1 ferret euthanised at day 5 & 8 post re-challenge	Activity =1; 2 Activity =2; 1
4	Naïve Sentinel	2 ferrets euthanised at day 20 pc	0	0	0		
5	Naïve Control					1 ferret euthanised at day 5 & 8 post re-challenge	Activity =1; 2

773 The table illustrates the summed scores for each clinical observation noted for each
774 of the groups during specific days post challenge and post re-challenge. Activity in
775 ferrets was scored as follows; 0 = alert and playful, 1 = alert, playful when stimulated,
776 2 = alert, not playful when stimulated, 3 = not alert or playful. Ruffled fur was given a
777 score of 1. Activity scores of 1 were given to ferrets during the initial challenge. Upon
778 re-challenge ferret activity was recorded as 1 or 2 indicating increased lethargy in
779 ferrets following re-challenge.

780



781

782 **Figure 3.** (a) Nasal cavity, day 3 pc, Group 1, H&E staining. Mild epithelial cell necrosis
783 (arrows) and minimal inflammatory cell infiltration within the epithelium. (b) Nasal
784 cavity, day 3 pc, Group 1, SARS-CoV-2 viral RNA detection (RNAScope staining).
785 Presence of viral RNA in abundant ciliated epithelia cells from the nasal cavity
786 mucosa. (c) Lung, day 5 pc, Group 1, H&E staining. Moderate bronchopneumonia with
787 neutrophil and macrophage inflammatory infiltrate within the bronchiolar lumina
788 (arrow). Mild peribronchiolar infiltration of mononuclear cells (*). (d) Lung, day 3 pc,
789 Group 2, SARS-CoV-2 viral RNA detection (RNAScope staining). Presence of viral
790 RNA in type II pneumocyte (arrow). (e) Lung, day 21 pc, Group 1, H&E staining. A
791 Bronchiole with mild inflammatory infiltration in the lumina (arrow) and attenuation of

792 the epithelial cells. Moderate peribronchiolar infiltration of mononuclear cells (*) and
 793 mild interalveolar septal inflammatory cell infiltration with thickening of the wall
 794 (arrowheads). (f) Liver, day 21 pc, Group 1, H&E staining. Moderate multifocal
 795 hepatitis with mononuclear cell infiltration in the portal areas (arrow).

796


797 **Table 3. Neutralising Antibodies to SARS-CoV-2**

Dose Group	8	11	14	20	21	26	30	33	36
High (Group 1)	105, 136, 183	194, 149, 290	136, 180, 262		234, 153				
Medium (Group 2)	125, 171, 29		48, 298, 86			274, 250	260, 289	>320, 320	>320
Low (Group 3)	43, 49, 42	125, 50, 96	74, 82, 17			82, 55	29, 41	52, 67	29
Naïve Sentinel (Group 4)		22, 120		125, 25					
Naïve Control (Group 5)							19, 197	20, 93	127

798

799 Numbers represent reciprocal of ND₅₀. Serum was tested using the plaque reduction
 800 neutralisation test from day 8 post challenge onwards. The second viral challenge was
 801 performed on day 28. Days 30, 33 and 36 represent days 2, 5 and 8 post re-challenge
 802 respectively.

803



804

805 **Figure 4. Re-challenge of ferrets with SARS-CoV-2** (a) Nasal washes were
806 collected at days 1-5 post re-challenge (days 29 – 33 post-original challenge). Viral
807 RNA was quantified by RT-qPCR. (b) Percentage weight change from baseline.
808 Baseline was calculated as average of the two most recent weights taken preceding
809 re-challenge. (c) Cellular immune responses of ferrets infected with SARS-CoV-2.
810 Lung MNCs were collected from animals (n= 1) at day 36 pc (day 8 following re-
811 challenge). SARS-CoV-2 specific IFN- γ responses were seen in both infected ferrets.
812 The values measured for each ferret are plotted as spot forming units (SFU) per million
Page 38 of 39

813 cells. **(d)** Medium dose re-challenged ferret at day 5 post re-challenge. No remarkable
814 changes in alveoli or terminal bronchiole. **(e)** Low dose re-challenged ferret at day 5
815 post re-challenge. No remarkable changes in alveoli or bronchiole. **(f)** Control group
816 ferret challenged for the first time (day 28 pc). Inflammatory infiltration within
817 bronchiolar lumen and mild infiltration of alveolar septa; lesions comparable with those
818 observed in the original high dose group.

819

820

821